Drug Development Pharma Companies Regulations 
Drug Target Review
DECEMBER 20, 2024
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.
Vial
FEBRUARY 15, 2024
Expertise in regulatory compliance : With deep regulatory knowledge, CROs assist sponsors in obtaining regulatory approvals, ensuring compliance with local regulations, and managing interactions with regulatory authorities. Their ability to adapt to evolving regulations and industry standards reduces the likelihood of costly setbacks.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JANUARY 9, 2025
Navigating the complex landscape of drug development and manufacturing can be a daunting task. Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. A: It’s never too early to start considering CDMO partnerships.
Metabolite Tales Blog
DECEMBER 19, 2023
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group A Metabolite Bioanalysis Working Group comprised of experts from 14 different pharma companies have proposed recommendations around best practice in metabolite bioanalysis during drug development.
Drug Target Review
MAY 23, 2023
The algae-derived non-digestible oligosaccharides can also influence the expression of cytokines that regulate the immune system. 9 Academic scientists researching natural products often struggle with the pitfalls of drug development. Regulation (EU) 2017/2470 maintains this list within the novel food catalogue.
H1 Blog
DECEMBER 11, 2024
Drug Policy There will be significant changes in clinical trials & drug development due to the Inflation Reduction Act. As pharmaceutical companies shift their focus toward fewer, high-value therapeutic areas in light of the IRAs drug price negotiations, the overall number of clinical trials will go down.
Altus Drug Development
JUNE 28, 2022
The development of new combination products containing previously unseen combinations of active substances. For instance, European pediatric regulation places certain requirements to support the safety and efficacy of drugs destined to be used on children ( source ). appeared first on Altus Drug Development.
Expert insights. Personalized for you.
128 
Let's personalize your content